CpG Oligonucleotide Immunotherapy for Cold Tumor Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods, including checkpoint inhibitors and TLR agonists, have limited efficacy due to immune suppression and the rarity of tumor-infiltrating lymphocytes, making them ineffective for most cancer types, and existing CpG ODNs induce significant IL-10 production, inhibiting anti-tumor responses.
Innovation Solution
The use of specific subtypes of CpG ODNs with reduced phosphorothioate modifications, administered intratumorally or peritumorally, in combination with checkpoint inhibitors and/or radiotherapy, to induce high levels of type I IFN and promote CD8+ T-cell infiltration and activation, converting 'cold' tumors to 'hot' ones amenable to treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If conventional CpG ODN with high phosphorothioate modifications are used, then immune stimulation is enhanced, but IL-10 production increases which inhibits anti-tumor responses
Solution Approach 1:
The patent applies parameter changes by modifying the phosphorothioate modification level of CpG ODN from conventional high modification to reduced modification (0-3 phosphorothioate modifications per oligonucleotide). This parameter change alters the immune response profile to reduce IL-10 production while maintaining anti-tumor activity through enhanced type I IFN induction and CD8+ T-cell activation
Solution Approach 2:
The patent creates a composite therapeutic approach by combining reduced-modification CpG ODN with checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) and/or radiotherapy. This composite material combination synergistically enhances anti-tumor responses by integrating the immune stimulation from CpG ODN with the checkpoint blocking effects and radiation-induced immunogenic cell death
2Reliability
If checkpoint inhibitors are administered alone, then anti-tumor activity is improved, but efficacy remains limited due to lack of tumor-infiltrating lymphocytes
Solution Approach 1:
The patent applies preliminary action by administering CpG ODN intratumorally or peritumorally before or concomitantly with checkpoint inhibitors to pre-establish immune activation and CD8+ T-cell infiltration. This preliminary immune stimulation creates a more favorable tumor microenvironment that enhances the subsequent efficacy of checkpoint inhibitors
Solution Approach 2:
The patent merges multiple therapeutic modalities by combining CpG ODN immunostimulation with checkpoint inhibition and/or radiotherapy into a unified treatment protocol. This combination approach addresses the limitations of single-agent therapy by integrating agents that act at different points in the cancer immunity cycle
3Power
If TLR agonists are used to stimulate immune response, then anti-tumor responses are promoted, but immune suppression increases due to IL-10 induction
Solution Approach 1:
The patent modifies the parameters of TLR9 agonists by using CpG ODN with reduced phosphorothioate modifications (0-3 modifications) instead of conventional high-modification formulations. This parameter change shifts the cytokine response profile to favor type I IFN production and reduce IL-10-mediated immune suppression, thereby enhancing net anti-tumor activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances immune activation and reduces inhibition, leading to improved anti-tumor responses and increased efficacy of checkpoint inhibitors, even in cancers with limited pre-existing immunity.
Implementation Method 1
CpG ODN bind and stimulate TLR9, an innate immune receptor which is constitutively expressed in only two type of human immune cell: B cells, which respond to TLR9 stimulation by proliferating and secreting immunoglobulin; and plasmacytoid dendritic cells (pDC), which respond to TLR9 stimulation by secreting large amounts of type I IFN (IFN-α and IFN-β)
Implementation Method 2
Type I IFN is believed to play a key role in tumor rejection. For example, Type I IFN augments CD8+ T-cell survival, expansion, and effector differentiation; promotes dendritic cell (DC) maturation, cross-presentation of tumor-associated antigens to CD8+ T cells
Implementation Method 3
delivery of the CpG ODN into tumors (directly or indirectly) induces the expression of adhesion molecules in the local vasculature in and around the tumor, and promotes the egress of activated T cells (CD4+ and CD8+) from capillaries into the tumor and surrounding region
Implementation Method 4
The cycle for induction of therapeutic immune responses against tumors may be broken down into seven distinct steps (FIG. 1): 1. Release of cancer cell antigens
Data Source
AI summary
Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.